Date: 2017-02-27
Type of information: Financing round
Company: Exonics Therapeutics (USA - TX)
Investors: CureDuchenne Ventures (USA - CA)
Amount: $ 5 million
Funding type: financing round
Planned used: This initial seed funding will allow Exonics Therapeutics to advance the preclinical research of its scientific founder and chief science advisor Eric Olson, PhD. Dr. Olson’s laboratory has demonstrated the ability to use adeno-associated virus to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin. Published preclinical data suggest that this approach has the potential to permanently treat up to 80 percent of children suffering from the disease. Additional preclinical data is expected to be published in March 2017.
Others: * On February 27, 2017, Exonics Therapeutics, a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, announced a commitment of $5 million in seed financing from CureDuchenne Ventures, LLC, a subsidiary of the nonprofit CureDuchenne.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
